POSTER PRESENTATIONS-SESSION II

ASTHMA/ALLERGY (including ARDS) 

ASTHMA/ALLERGY (including ARDS)-Clinical Outcomes Studies 

PAA1
MEASURING THE IMPACT OF AN ASTHMA DISEASE MANAGEMENT INTERVENTION ON PHARMACY AND IN-PATIENT SERVICE UTILIZATION IN A MANAGED CARE SETTING
Patel VD¹, Weingarten J², Wedemeyer D², Ershoff D³, Horwitz K^1
1University of Southern California, Los Angeles, CA, USA; ²Care 1st Health Plan, Alhambra, CA, USA; ³AstraZeneca, Encino, CA, USA  

PAA2

THE PREVALENCE OF INAPPROPRIATE USE OF SHORT-ACTING ASTHMA MEDICATION
Hong SH
University of Arkansas for Medical Sciences, Little Rock, AR, USA

PAA3

WEB-ENABLED ASTHMA APPLICATION FOR PERSONALIZED MEDICAL COMMUNICATION WITHIN A MULTI-GROUP PRACTICE SETTING
Arnold RJ¹, Kaniecki DJ¹, Rosen J^2
1Pharmacon International, Inc, New York, NY, USA; ²ProHealth Physicians, Bristol, CT, USA

PAA4

INHALED SALMETEROL UTILIZATION AND ASTHMA PATIENT OUTCOMES IN A GROUP-MODEL MANAGED CARE ORGANIZATION
Plauschinat CA¹, Browne B¹, Godley P¹, Weldon DR^2
1Scott & White Memorial Hospital, Temple, TX, USA; ²Scott & White Clinic in College Station, College Station, TX, USA  

ASTHMA/ALLERGY (including ARDS)-Cost Studies 

PAA5
LOCAL ADVERSE EVENT RATES AND COSTS ASSOCIATED WITH INHALED CORTICOSTEROIDS USE
Chow W¹, Concetta C¹, Szwarcberg J¹, Lee D², Patton M², Haberman M², Goldberg G², Broderick W^2
1Aventis Pharmaceuticals, Bridgewater, NJ, USA; ²Constella Health Strategies, Durham, NC, USA  
 

PAA6
RACIAL DIFFERENCES IN PHARMACOTHERAPY AND HEALTH CARE EXPENDITURES FOR THE TREATMENT OF ASTHMA IN A MEDICAID POPULATION
Hawkins K¹, Stanford RH², Orsini LS³, Ozminkowski RJ¹, Jiang C^4
1The MEDSTAT Group, Inc, Ann Arbor, MI, USA; ²GlaxoSmithKline, RTP, NC, USA; ³The MEDSTAT Group, Inc, Cambridge, MA, USA; ⁴The MEDSTAT Group, Inc, Santa Barbara, CA, USA  

PAA7
HEALTH CARE EXPENDITURES OF PATIENTS WITH COMORBID ALLERGIC RHINITIS AND ASTHMA
Chang S¹, Long S¹, Leahy M², Crown WH^3
1Medstat, Washington, DC, USA; ²Aventis Pharmaceutical, Bridgewater, NJ, USA; ³The MEDSTAT Group, Cambridge, MA, USA  

PAA8
THE EFFECT OF HAVING A PRIMARY CARE PROVIDER ON ASTHMA HEALTH CARE EXPENDITURE AND HEALTH CARE UTILIZATION
Nurmagambetov T, Atherly A, Williams S, Redd S
Centers for Disease Control and Prevention, Atlanta, GA, USA  

PAA9

ASTHMA-RELATED HEALTH CARE SERVICES UTILIZATION BY AFRICAN-AMERICANS IN A MEDICAID POPULATION
Pawar VS, Smith MJ
West Virginia University, Morgantown, WV, USA

Prior surveillance has shown that higher rates of morbidity and mortality related to asthma occur among African-Americans compared to other ethnic groups.

PAA10
BUDGET IMPACT ANALYSIS: COMBINATION FLUTICASONE AND SALMETEROL FOR ASTHMA
Mauskopf J¹, Shih T², Baker T³, Borker R⁴, Stanford R⁴, Jhingran P^4
1RTI Health Solutions, Research Triangle Park, NC, USA; ²The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA; ³MEDTAP, Bethesda, MD, USA; ⁴GlaxoSmithKline, RTP, NC, USA  

PAA11

EFFECTIVENESS AND COST-BENEFIT OF LEUKOTRIENE MODIFIERS IN ADULTS WITH ASTHMA IN THE OHIO MEDICAID POPULATION
Heaton PC, Guo JJ, Jang R, Cluxton RJ
University of Cincinnati, Cincinnati, OH, USA

PAA12

RESOURCE UTILIZATION (HOSPITAL AND PHYSICIAN COST/VISITS) BEFORE AND AFTER INTRODUCTION OF THE NEW TREATMENT GUIDELINES IN ASTHMA (1997) AND ODDS OF BEING ON APPROPRIATE ASTHMA THERAPY USING MULTIVARIATE LOGISTIC REGRESSION
Mehta R, Cady P
Idaho State University, Salt Lake City, UT, USA

PAA13

COSTS FOR ASTHMA-RELATED MEDICAL SERVICES AND PRESCRIPTION MEDICATIONS IN A STATE MEDICAID PROGRAM
D'Souza A, Smith M
West Virginia University, Morgantown, WV, USA
 

PAA14

THE EFFECT OF MEDICAID COVERAGE DECISIONS ON NON-SEDATING ANTIHISTAMINE UTILIZATION AND SPENDING FOLLOWING OVER-THE-COUNTER AVAILABILITY OF LORATADINE
Hansen RA, Trygstad TK
University of North Carolina - Chapel Hill, Chapel Hill, NC, USA  

PAA21
AFFECT OF PAYMENT SOURCES ON THE DIAGNOSTIC TESTS PRESCRIBING FOR PEDIATRIC ASTHMA
Rahman A
St. John's University, Jamaica, NY, USA

ASTHMA/ALLERGY (including ARDS)-Quality Of Life/Adherence/Patient Preferences

PAA15

INVESTIGATION OF THE DETERMINANTS OF ADHERENCE IN ASTHMA USING Q METHODOLOGY
Butler MG¹, Schumock GT², Wilken L², Jaffe HA², Mrtek R^2
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ²University of Illinois at Chicago, Chicago, IL, USA

PAA16
PREDICTORS OF SELF-REPORTED ADHERENCE IN PATIENTS WITH ASTHMA
De Smet BD, Erickson SR, Kirking DM
University of Michigan, Ann Arbor, MI, USA  

PAA17
THE ASSOCIATION BETWEEN ADHERENCE, ASTHMA CONTROL, GENERIC AND DISEASE SPECIFIC QUALITY OF LIFE INSTRUMENTS IN ASTHMA
Franic DM¹, Larry A¹, Oyelowo O¹, Grauer D^2
1University of Georgia, Athens, GA, USA; ²The University of Kansas, Kansas City, KS, USA  

PAA18
THE ASSOCIATION BETWEEN MEASURES OF HEALTH STATE UTILITIES, QUALITY OF LIFE AND WILLINGNESS TO PAY IN ASTHMA.
Franic DM, Aull L, Oyelowo O
The University of Georgia, Athens, GA, USA

PAA19
CONSUMER SATISFACTION WITH ASTHMA TREATMENT – WHAT MATTERS?
Prütz C¹, Karlsson G¹, Ovanfors A², Pilman E³, Brun J¹, Westlund A^4
1AstraZeneca Sweden, Södertälje, Sweden; ²CFI Group, Stockholm, Sweden; ³Statena Primary Care Centre, Helsingborg, Sweden; ⁴Stockholm School of Economics, Stockholm, Sweden  

PAA20

PREFERENCE SCORES FROM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) PATIENTS
Sakthong P¹, Gross CR¹, Treesak C^2
1University of Minnesota, Minneapolis, MN, USA; ²Srinakharinwirot University, Nakhornnayok, Thailand

BLOOD RELATED STUDIES 

BLOOD RELATED STUDIES -Cost Studies 

PBR1
THE ECONOMIC BURDEN OF ANEMIA IN AN INSURED POPULATION
Wade SW¹, Knight K¹, Wilson A¹, Dubois R¹, Goodnough LT², Nissenson AR^3
1Zynx Health, Beverly Hills, CA, USA; ²National Anemia Action Council and Washington University, St. Louis, MO, USA; ³National Anemia Action Council and David Geffen School of Medicine, Los Angeles, CA, USA  

PBR2

WITHDRAWN

BLOOD RELATED STUDIES -Quality of Life Studies 

PBR3
THE HEALTH-RELATED QUALITY OF LIFE EXPERIENCES OF YOUNG ADULTS WITH SICKLE CELL DISEASE: A QUALITATIVE ASSESSMENT
Mehta SR, Mayhew DY, De Leon JM, Hartzema AG, Lottenberg R
University of Florida, Gainesville, FL, USA

BLOOD RELATED STUDIES -Health Policy Studies 

PBR4
BLOOD DONATION IN THE 21ST CENTURY: MOTIVATION AMIDST CRISIS
Gabriel Z, Richard L
Heron Evidence Development, Letchworth, Herts, United Kingdom

BLOOD RELATED STUDIES -Methods

PBR5
GREATER AREA UNDER THE HEMOGLOBIN CHANGE CURVE DURING EPOETIN ALFA TREATMENT IS ASSOCIATED WITH IMPROVED PATIENT OUTCOMES
Lefebvre P¹, Fastenau JM², Duh MS¹, Cremieux P¹, McKenzie RS², Piech CT^2
1Analysis Group, Inc, Boston, MA, USA; ²Ortho Biotech Products, L.P, Bridgewater, NJ, USA  

PBR6

REPORT FROM THE FIRST MULTIDISCIPLINARY COST OF BLOOD CONSENSUS (COBCON) WORKING GROUP TO ESTABLISH STANDARD METHODOLOGY
Broder M¹, for the COBCON Working Group (SABM)², Aledort LM³, Busch MP⁴, Custer B⁴, Fergusson DA⁵, Goodnough LT⁶, Hendler RS⁷, Hofmann A⁸, Klein HG⁹, Louie JE¹⁰, Page PL¹¹, Sazama K¹², Shander A¹³, Shulman IA¹⁴, Spence RK¹⁵, Sullivan MT¹⁶, Thurer RL^17
1Zynx Health, A Cerner Company, Beverly Hills, CA, USA; ²Society for the Advancement of Blood Management, Englewood, NJ, USA; ³Mount Sinai School of Medicine, New York, NY, USA; ⁴The Pacific/Blood Systems, Inc., San Francisco, CA, USA; ⁵University of Ottawa Centre for Transfusion Research, Ottowa, ON, Canada; ⁶Washington University School of Medicine, St. Louis, MO, USA; ⁷Tenet Health Systems, Dallas, TX, USA; ⁸SABM-Austria, Vienna, Austria; ⁹Warren G. Magnuson Clinical Center, Bethesda, MD, USA; ¹⁰New York Blood Center, New York, NY, USA; ¹¹American Red Cross, Washington,  D.C., USA; ¹²University of Texas MD Anderson Cancer Center, Houston, TX, USA; ¹³Mount Sinai School of Medicine and Englewood Hospital and Medical Center, Englewood, NJ, USA; ¹⁴Keck School of Medicine of the University of Southern California, Los Angels, CA, USA; ¹⁵St. Agnes Heatlh Care; ¹⁶National Blood Data Resource Center, Baltimore, MD, USA; ¹⁷Harvard Medical School and Beth Israel Medical Center, Boston, MA, USA

CARDIOVASCULAR DISEASE (including Obesity) 

CARDIOVASCULAR DISEASE (including Obesity)-Clinical Outcomes Studies

PCV1
ZIPRASIDONE VS OLANZAPINE: CONTRASTS IN CHD RISK
Leaderer M, Harrison DJ, Loebel A, Murray S
Pfizer Inc, New York, NY, USA

PCV2
COMBINED LIPID GOAL ATTAINMENT IN THE MANAGED CARE SETTING
Sarawate C¹, Bullano MF¹, Cziraky MJ¹, Willey VJ¹, Schrader BJ², Charland SL², Stanek EJ^2
1Health Core, Inc, Newark, DE, USA; ²Kos Pharmaceuticals, Inc, Weston, FL, USA

PCV3
USING HEALTH-RISK APPRAISAL DATA FOR ASSESSING PREDICTORS OF HYPERTENSION TREATMENT
Brown JS¹, Menzin J¹, Manocchia M^2
1Boston Health Economics, Inc, Waltham, MA, USA; ²Blue Cross Blue Shield of Rhode Island, Providence, RI, USA

PCV4
WITHDRAWN

PCV5
PREDICTORS OF ADHERENCE WITH CONCOMITANT ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY
Chapman RH¹, Benner JS¹, Petrilla AA¹, Tierce JC¹, Battleman DS², Schwartz JS^3
1ValueMedics Research, LLC, Arlington, VA, USA; ²Pfizer Inc, New York, NY, USA; ³University of Pennsylvania, Philadelphia, PA, USA 

PCV6
ANALYZING RISK OF BLEEDING IN ADMINISTERING LOW MOLECULAR WEIGHT HEPARINS AND/OR ASPIRIN TO ORTHOPEDIC PATIENTS
yin H¹, Vogenberg FR^2
1University of Illinois, Chicago, IL, USA; ²Aon Consulting Co, Wellesley, MA, USA

PCV7
WITHDRAWN
 

PCV8
WARFARIN ANTICOAGULATION AND OUTCOMES IN ATRIAL FIBRILLATION PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Reynolds MW¹, Nalysnyk L¹, Fahrbach K¹, Hauch O², Wygant G², Estok R¹, Frame D¹, Cella C¹, Scheye R¹, Ross S^1
1Metaworks, Inc, Medford, MA, USA; ²AstraZeneca, L.P, Wilmington, DE, USA

PCV9
LIPID MANAGEMENT AND FACTORS AFFECTING GOAL ATTAINMENT IN LATIN AMERICA
Meaney E¹, Armaganijan D², Ruiz A³, Ramos A⁴, Alemao E⁵, Yin D^5
11o. Octubre Hospital, Mexico City, Mexico; ²Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil; ³Universidad Pontificia, Bogotá, Colombia; ⁴Innoval, Mexico City, Mexico; ⁵Merck & Co, Whitehouse Station, NJ, USA

PCV10
THE IMPACT OF ADEQUATE MONITORING OF LIPID LEVELS IN PATIENTS HAVING ELECTIVE PERCUTANEOUS CORONARY INTERVENTIONS IN A LOCAL PUBLIC HOSPITAL IN HONG KONG
Lee VW¹, Chan WK², Lee KK^1
1The Chinese University of Hong Kong, Shatin, Hong Kong, China; ²United Christian Hosptial, Kwun Tong, Hong Kong, China

PCV11
EVALUATING CLINICAL OUTCOMES FOR SUBJECTS THAT ARE NEWLY INITIATED ON HMG-COA REDUCTASE INHIBITORS IN A NATURALISTIC ENVIRONMENT USING LONGITUDINAL DESIGN
Al-Zakwani I¹, Bullano MF¹, Willey VJ¹, Cziraky MJ¹, Hoffman L^2
1Health Core, Inc, Newark, DE, USA; ²Blue Cross and Blue Shield of Florida, Jacksonville, FL, USA

PCV12
UTILIZATION PATTERNS OF HYPERTENSION THERAPIES AMONG PATIENTS INITIATING ANGIOTENSION II RECEPTOR ANTAGONIST THERAPY
Young CH¹, Zhang K¹, Poret AW^2
1AdvancePCS, Hunt Valley, MD, USA; ²Boehringer Ingelheim Pharmaceuticals, Inc., Ingelheim, Germany

PCV13
RECENT EVIDENCE SURROUNDING THE EFFICACY OF PROTECTED CAROTID ANGIOPLASTY WITH STENTS
Burton K
University of Toronto, Toronto, ON, Canada

PCV14
A COMPARISON OF THE RISK OF ADVERSE THROMBOEMBOLIC AND BLEEDING EVENTS BETWEEN SUBJECTS TREATED AND NOT TREATED WITH WARFARIN
Riedel A¹, Hauch O², Harley C¹, Nelson M¹, Wygant G², Reynolds M^2
1Ingenix, Eden Prairie, MN, USA; ²AstraZeneca, L.P, Wilmington, DE, USA
 

CARDIOVASCULAR DISEASE (including Obesity)-Cost Studies

PCV15
ECONOMIC EVALUATION OF GLYCOPROTEIN IIB/IIIA ANTAGONISTS IN DIABETIC PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS WITH STENTING
Mittmann N¹, Brown A², Seung SJ³, Noorani H², Mensinkai S², Cohen E⁴, Risebrough N³, Oh P⁵, Tang Z^2
1HOPE Research Centre, Toronto, ON, Canada; ²Canadian Coordinating Office For Health Technology Assessment (CCOHTA), Ottowa, ON, Canada; ³HOPE Research Centre, Toronto, ON, Canada; ⁴Sunnybrook & Women's College Health Sciences Centre, Toronto, ON, Canada; ⁵Toronto Rehabilitation Institute (Rumsey Centre), Toronto, ON, Canada

PCV16
DIFFERENCES IN RESOURCE UTILIZATION IN POST-MI PATIENTS WITH AND WITHOUT HEART FAILURE
Arondekar BV¹, Basu A², Manning WG², Walton SM^1
1University of Illinois at Chicago, Chicago, IL, USA; ²University of Chicago, Chicago, IL, USA

PCV17
A COST-UTILITY ANALYSIS OF LOSARTAN VERSUS ATENOLOL IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION
Anis AH¹, Sun H¹, Singh S², Woolcott J³, Nosyk B^2
1University of British Columbia, Vancouver, BC, Canada; ²Canadian HIV Trials Network, Vancouver, BC, Canada; ³BC Centre for Disease Control, Vancouver, BC, Canada

PCV18
COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PRAVASTATIN, AND SIMVASTATIN
Benner JS¹, Smith TW¹, Klingman D¹, Tierce JC¹, Mullins CD², Pethick N³, O'Donnell J^3
1ValueMedics Research, LLC, Arlington, VA, USA; ²University of Maryland, Baltimore, MD, USA; ³Astrazeneca LP, Wilmington, DE, USA

PCV19
GENDER AND STATIN THERAPY COST AND EFFICACY
Larsen TL, Smith DG
University of Michigan, Ann Arbor, MI, USA

PCV20
RATES OF HYPERTENSION-RELATED MEDICAL AND PRESCRIPTION UTILIZATION AND COSTS IN A STATE MEDICAID POPULATION
Mody RR, Smith MJ
West Virginia University, Morgantown, WV, USA

Hypertension, a major risk factor for cardiovascular diseases such as stroke and myocardial infarction, affects approximately 50 million adults in the United States.

PCV21
PREVALENCE AND COST IMPLICATIONS OF POTENTIAL INTERACTIONS WITH STATIN MEDICATIONS IN A MANAGED CARE POPULATION
Etemad LR¹, Fairchild C², Waldeck R^2
1Ingenix, Eden Prairie, MN, USA; ²Bristol-Myers Squibb, Princeton, NJ, USA

PCV22
COST AND COMORBIDITIES ASSOCIATED WITH ATRIAL FIBRILLATION IN DIFFERENT AGE GROUPS
Wu EQ, Birnbaum H, Milena M
Analysis Group Inc, Boston, MA, USA

PCV23
HEALTH CARE AND DRUG UTILIZATION PATTERNS IN PATIENTS RECEIVING LONG TERM THIENOPYRIDINE THERAPY
McCollam PL¹, Lage M², Bowman L^1
1Eli Lilly and Company, Indianapolis, IN, USA; ²HealthMetrics Outcomes Research, Groton, CT, USA

 

PCV24
7309 HEALTH CARE RESOURCE UTILIZATION BY PATIENTS WITH ESSENTIAL HYPERTENSION
Nair RR, Bollu VK, Blake SG
The University of Louisiana at Monroe, Monroe, LA, USA

PCV25
TOBACCO COST-EFFECTIVENESS ANALYSES AND THE PAYER: IS THE SHORT TERM LONG OVERDUE?
Reed KE, Wieck SG, Tengs TO
Milliman USA, Denver, CO, USA

PCV26
MEDICARE EXPENDITURES IN RELATION TO FUNCTIONAL HEALTH STATUS POST-STROKE FOR A NATIONALLY-REPRESENTATIVE SAMPLE OF MEDICARE BENEFICIARIES FROM 1996 TO 2000
Singhal PK, Stuart B, Menis M, Kamal-Bahl S
University of Maryland, Baltimore, MD, USA

PCV27
HOSPITALIZATION COSTS AND LENGTH OF STAY IN POST-MI PATIENTS WITH HEART FAILURE
Arondekar BV¹, Basu A², Walton SM¹, Akhras K^3
1University of Illinois at Chicago, Chicago, IL, USA; ²University of Chicago, Chicago, IL, USA; ³Pfizer Inc, Skokie, IL, USA

PCV28
AN ARB COST-EFFECTIVENESS MODEL IN TREATING MILD-TO-MODERATE HYPERTENSION
Smolen HJ¹, Klein RW¹, Ohsfeldt RL², Poret AW³, Weinberger MH^4
1Medical Decision Modeling Inc, Indianapolis, IN, USA; ²University of Iowa, Iowa City, IA, USA; ³Boehringer Ingelheim Pharmaceuticals, Inc., Ingelheim, Germany; ⁴Indiana University, Indianapolis, IN, USA

PCV29
COST EFFECTIVENESS ANALYSIS OF THERAPY MODIFICATION AFTER FAILING STATIN TREATMENT
Grauer DW¹, Franic DM², Sullins G^1
1The University of Kansas, Kansas City, KS, USA; ²The University of Georgia, Athens, GA, USA

PCV30
WITHDRAWN

PCV31
ECONOMIC ANALYSIS OF AMIODARONE, ATRIAL SEPTAL PACING, AMIODARONE PLUS ATRIAL SEPTAL PACING VERSUS STANDARD OF CARE TO PREVENT ATRIAL FIBRILLATION AFTER OPEN-HEART SURGERY
Reddy P¹, Kalus J², Caron MF², Horowitz S², Karapanos A³, Coleman CI³, Kluger J², White CM^3
1Abt Associates Clinical Trials, Cambridge, MA, USA; ²Hartford Hospital, Hartford, CT, USA; ³University of Connecticut, Storrs, CT, USA

PCV32
WITHDRAWN

PCV33
COST ANALYSIS OF A PRIOR AUTHORIZATION PROGRAM FOR ANTI-OBESITY THERAPY IN A MEDICAID POPULATION
Grauer DW, Karpinski TA
¹The University of Kansas, Kansas City, KS, USA

CARDIOVASCULAR DISEASE (including Obesity)-Quality Of Life/Patient Preference/Adherence Studies

PCV34
QUALITY OF LIFE FROM THE MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE FOLLOWING AORTIC VALVE REPLACEMENT SURGERY
Sonnad SS¹, Lee B¹, Pagani FD², Bolling SF², Deeb GM^2
1University of Pennsylvania, Philadelphia, PA, USA; ²University of Michigan, Ann Arbor, MI, USA  

PCV35
VALIDATION OF THE EQ-5D QUESTIONNAIRE IN PATIENTS WITH A HISTORY OF ACUTE CORONARY SYNDROME
Ellis JJ¹, Eagle KA², Kline-Rogers EM², Rogers B², Erickson SR^2
1Cleveland Clinic Foundation, Cleveland, OH, USA; ²University of Michigan, Ann Arbor, MI, USA

PCV36
THE IMPACT OF ACEI RELATED COUGH: A SURVEY OF AUSTRALIAN PATIENTS
Adams J¹, Le Reun C², Heavey M², Burke M², Flowers M³, Germanos P⁴, Lindsay P⁵, Noble P⁶, Webb K⁷, Davey P^1
1M-TAG, Chatswood, NSW, Australia; ²Bristol-Myers Squibb Australia, Nobel Park, Vic, Australia; ³Astra-Zeneca Australia, North Ryde, NSW, Australia; ⁴Boehringer-Ingelheim Pty Ltd, North Ryde, NSW, Australia; ⁵GlaxoSmithKline, Boronia, Vic, Australia; ⁶Solvay Pharmaceuticals, Pymble, NSW, Australia; ⁷Sanofi-Synthelabo, North Ryde, NSW, Australia

PCV37
HEALTH-RELATED QUALITY OF LIFE OF PATIENTS MAKING AN ATTEMPT AT SMOKING CESSATION
Erickson SR, Thomas LA, Blitz SG
University of Michigan, Ann Arbor, MI, USA  

PCV38
HEALTH-RELATED QUALITY OF LIFE IN AN ACUTE CORONARY SYNDROME POPULATION IS AFFECTED BY DEPRESSION TREATMENT ADEQUACY
Ellis JJ¹, Eagle KA², Kline-Rogers EM², Rogers B², Erickson SR^2
1Cleveland Clinic Foundation, Cleveland, OH, USA; ²University of Michigan, Ann Arbor, MI, USA

 

PCV39
HEALTH STATUS IN HIGH-RISK PATIENTS UNDERGOING NONCARDIAC VASCULAR SURGERY IN THE UNITED STATES
Sheikh S¹, Haider S¹, Joseph C C¹, Lee WC², Gold K², Stephens J², Fleisher LA^3
1Pfizer Inc, Groton, CT, USA; ²Abt Associates Inc, Bethesda, MD, USA; ³University of Pennsylvania Medical Center, Philadelphia, PA, USA

PCV40
ASSESSMENT OF THE QUALITY OF DRUG TREATMENT IN CORONARY ARTERY DISEASE USING QUALITY INDICATORS
Szalayova A, Dubrava M
Comenius University, Bratislava, Slovak Republic

PCV41
MEDICATION POSSESSION RATIOS FOR PATIENTS WITH CALCIUM CHANNEL BLOCKERS AND/OR STATINS
Nichol MB¹, Shi S¹, Knight TK¹, Livengood K², Ambegaonkar AJ^2
1University of Southern California, Los Angeles, CA, USA; ²Pfizer Inc, New York, NY, USA

PCV42
PERSISTENCE AND ADHERENCE TO STATIN THERAPY IN A MANAGED CARE SETTING
Quach C¹, Nichol MB², Chen L¹, Patel BV¹, Berenbeim D^1
1MedImpact Health care Systems Inc, San Diego, CA, USA; ²University of Southern California, Los Angeles, CA, USA

PCV43
EVALUATION OF THE ASSOCIATION BETWEEN HEALTH-RELATED UTILITY AND OBESITY IN HOSPITAL TREATED SUBJECTS
Currie CJ¹, Dixon S², Morrissey M³, Farina C⁴, Peters JR⁵, McEwan P^6
1University of Wales College of Medicine, Cardiff, Wales, United Kingdom; ²Sheffield University, Sheffield, South Yorkshire, United Kingdom; ³Cardiff Research Consortium, Cardiff, Wales, United Kingdom; ⁴Roche Ltd, Welwyn Garden City, Hertfordsire, United Kingdom; ⁵University Hospital of Wales, Cardiff, Wales, United Kingdom; ⁶Cardiff University, Cardiff, Wales, United Kingdom

PCV44
BMI, SELF-REPORTED COMORBIDITIES, AGE, AND GENDER DO NOT EXPLAIN COUNTRY-SPECIFIC DIFFERENCES IN OBESITY-RELATED QUALITY OF LIFE
Hayes RP, Bowman L
Eli Lilly & Company, Indianapolis, IN, USA

PCV45
WITHDRAWN

CARDIOVASCULAR DISEASE (including Obesity)-Health Policy Studies 

PCV46
EXPLORATION OF HIGHLY ELEVATED CREATININE KINASE RESULTS AND ASSOCIATED CHOLESTEROL THERAPY IN A LARGE COMMERCIAL HEALTH PLAN
Harley C¹, Kempf J², Nelson M¹, Riedel A^1
1Ingenix, Eden Prairie, MN, USA; ²AstraZeneca LP, Wilmington, DE, USA

PCV47
THE NATIONAL ANTICOAGULATION BENCHMARK AND OUTCOMES REPORT (NABOR™): EVIDENCE OF A SIGNIFICANT DIFFERENCE BETWEEN GUIDELINES AND ACTUAL PRACTICE
Shillington A¹, Tapson V², Hyers T³, Becker R², Colgan K^1
1EPI-Q, Inc, Oakbrook Terrace, IL, USA; ²Duke University Medical Center, Durham, NC, USA; ³CARE Clinical Research, St. Louis, MO, USA

PCV48
OBESITY AMONG HIGH SCHOOL STUDENT AND CONTRIBUTING FACTORS
Williams BD, Xiao H
Florida Agricultural & Mechanical University, Tallahassee, FL, USA

PCV49
DOES THE RATE OF MEDICARE MANAGED-CARE PENETRATION AFFECT AVAILABILITY OF RESOURCES FOR HEART FAILURE TREATMENT?
Masselink LE¹, Friedman JY¹, Whellan DJ², Schulman KA^1
1Duke Clinical Research Institute, Durham, NC, USA; ²Duke University Medical Center, Durham, NC, USA

PCV50
GASTRIC BYPASS SURGERY – AN OVERVIEW
Misra S
Rush University Medical Center, Chicago, IL, USA

PCV51
RETROSPECTIVE EVALUATION OF UTILIZATION PATTERNS OF BETA-BLOCKER THERAPY IN CONGESTIVE HEART FAILURE PATIENTS IN A MANAGED CARE ENVIRONMENT
Thaker DJ, Godley PJ, Browne BA, Rohack J, Houck P
Scott & White, Temple, TX, USA

PCV52
IMPACT OF MARKET FORCES ON STATIN PERSISTENCE PATTERS IN A CALIFORNIA MEDICAID POPULATION
Nichol MB¹, Shi S¹, Knight TK¹, Popovian R², Morita R^2
1University of Southern California, Los Angeles, CA, USA; ²Pfizer, Inc, New York, NY, USA

PCV53
IMPACT OF THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT) ON PHYSICIAN PRESCRIBING PATTERNS AND PATIENT UTILIZATION OF ANTIHYPERTENSIVE MEDICATIONS
Liu X, Yu W, Yokoyama K
WellPoint Pharmacy Management, West Hills, CA, USA

PCV54
IMPACT OF THE NATIONAL SERVICE FRAMEWORK (NSF) FOR CORONARY ARTERY DISEASE (CAD) ON PHYSICIAN COMPLIANCE OF PRESCRIBING ASPIRIN AND STATINS FOR SECONDARY PREVENTION IN THE UNITED KINGDOM (UK)
Pradhan A¹, Ray S², Cislo P^2
1Bristol Myers Squibb, London, United Kingdom; ²Bristol Myers Squibb, Wallingford, CT, USA

PCV55
DELAY IN DIAGNOSIS AS A FACTOR IN INITIATION OF TREATMENT FOR HYPERCHOLESTEROLAEMIA
O'Regan CP¹, Lister SP², Marchant NJ^1
1Pfizer UK Limited, Walton on the hill, United Kingdom; ²Compufile Limited, Woking, United Kingdom  

PCV56
DELAY IN DIAGNOSIS AS A FACTOR IN INITIATION OF TREATMENT FOR HYPERTENSION
O'Regan CP¹, Lister SP², Marchant NJ^1
1Pfizer UK Limited, Walton on the hill, United Kingdom; ²Compufile Limited, Woking, United Kingdom

PCV57
ASSOCIATION BETWEEN INSURANCE COVERAGE AND OUTCOMES FOR INDIVIDUALS HOSPITALIZED FOR NONHEMORRHAGIC STROKE
Okafor MC, Thomas III J
Purdue University, West Lafayette, IN, USA

PCV58
USE OF GPIIB/IIIA INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WITH DRUG-ELUTING STENTS
Young J, Foster D, Heller S
Solucient, LLC, Ann Arbor, MI, USA  

PCV59
CLINICAL PHARMACIST INVOLVMENT IN COMMUNITY ANTICOAGULATION CONTROL
Guy-Alfandary S, Raz M, Timkin N, Triki N, Katz M
Maccabi Healthcare Services, Azur, Israel

PCV60
DISORDERS OF LIPOID METABOLISM: LIKELIHOOD OF PRESCRIPTION THERAPY
Hess GP, Lipskiy N
Surveillance Data, Plymouth Meeting, PA, USA

DIABETES (including Parathyroid Disease)

DIABETES (including Parathyroid Disease)-Clinical Outcomes Studies

PDB1
LOWER INCIDENCE OF MICROVASCULAR EVENTS ASSOCIATED WITH PIOGLITAZONE MONOTHERAPY THAN INSULIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES: A RETROSPECTIVE PROPENSITY SCORE MATCHED COHORT ANALYSIS.
Rajagopalan R¹, Xu Y¹, Rosenson R^2
1Takeda Pharmaceuticals North America Inc, Lincolnshire, IL, USA; ²Northwestern University, Feinberg School of Medicine, Chicago, IL, USA

PDB2
COMPARISON OF PIOGLITAZONE WITH OTHER ANTIDIABETIC DRUGS FOR ASSOCIATED INCIDENCE OF LIVER FAILURE: NO EVIDENCE OF INCREASED LIVER FAILURE WITH PIOGLITAZONE
Rajagopalan R, Iyer S, Perez A
Takeda Pharmaceuticals North America Inc, Lincolnshire, IL, USA

PDB3
EVALUATION OF PHARMACIST INTERVENTIONS IN DIABETIC PATIENTS FROM RURAL COMMUNITY HEALTH CENTERS
Pinto S, Segal R, Winterstein A, Annis L, Robinson D, Yates D, Pederson L, Willis M
University of Florida, Gainesville, FL, USA

PDB4
PARTICIPATION IN HOME-BASED A1C TESTING IN CAREPATTERNS® PROGRAM FOR DIABETES
Berger J, Low D, Hu L, Stine N
Caremark, Northbrook, IL, USA

PDB5
SELF-MONITORING OF BLOOD GLUCOSE AMONG VETERANS WITH DIABETES MANAGED ON ORAL THERAPY
Wen L¹, Parchman M², Linn W¹, Lee S^1
1Audie L. Murphy Division, South Texas Veterans Health Care System, San Antonio, TX, USA; ²University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

PDB6
GENDER DISPARITY IN THE MANAGEMENT OF DYSLIPIDEMIA AMONG TYPE 2 DIABETES PATIENTS IN A MANAGED-CARE SETTING
Mallya UG, Nau DP
University of Michigan, Ann Arbor, MI, USA  

PDB7
ALTERNATIVE ANTIPSYCHOTIC TREATMENT AND RISK OF DIABETES: RESULTS FROM NC MEDICAID POPULATION
Sun SX, Liu GG, Christensen DB
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PDB8
THE ROLE OF INTRAOPERATIVE PARATHYROID HORMONE MONITORING FOR PARATHYROID HYPERPLASIA
Misra S
Rush University Medical Center, Chicago, IL, USA

DIABETES (including Parathyroid Disease)-Cost Studies 

PDB9
POTENTIAL MEDICAL COST REDUCTION DUE TO DECREASES IN A1C RESULTING FROM PHARMACIST DIABETES EDUCATON AND MEDICATION RECOMMENDATIONS IN A COMMUNITY SETTING
Gunderson SM, Lee KY, Duvel AH, Luce DF
Walgreens Health Initiatives, Deerfield, IL, USA

PDB10
UTILIZATION PATTERNS OF DRUGS AND HEALTH CARE SERVICES AMONG RECIPIENTS WITH DIABETES IN A MEDICAID POPULATION
Sundaram M, Smith MJ
West Virginia University, Morgantown, WV, USA

PDB11
DIFFERENCES IN HYPOGLYCEMIA EVENT RATES AND ASSOCIATED COST-CONSEQUENCE IN PATIENTS INITIATED ON LONG-ACTING AND INTERMEDIATE-ACTING INSULIN PRODUCTS
Bullano MF¹, Al-Zakwani I¹, Barron JJ¹, Menditto L², Willey VJ^1
1Health Core, Newark, DE, USA; ²Aventis Pharmaceuticals, Inc, Parsippany, NJ, USA

PDB12
ESTIMATING THE REDUCTION IN LONG TERM COMPLICATION AND COSTS OF COMPLICATIONS IN TYPE 1 DIABETES BY REDUCED A1C LEVELS DUE TO MORE FREQUENT BLOOD GLUCOSE MONITORING
Nicklasson L¹, Palmer A², Roze S^2
1Novo Nordisk Pharmaceuticals Inc, Princeton, NJ, USA; ²CORE Center for Outcomes Research, Basel, Switzerland

PDB13
PHARMACY AND MEDICAL RESOURCE UTILIZATION AMONG INITIAL METFORMIN AND THIAZOLIDINEDIONE PATIENTS
Shaya FT¹, Shin JY¹, Mullins CD¹, Foster S², Fatodu H^2
1University of Maryland, Baltimore, MD, USA; ²Johns Hopkins Health care LLC, Glen Burnie, MD, USA

PDB14
PROPENSITY SCORE METHODS FOR REDUCING BIAS IN THE COMPARISON OF COSTS AND UTILIZATION BETWEEN INSULIN LISPRO AND REGULAR INSULIN
Chen K¹, Chang E¹, Summers K², Obenchain R³, Yu-Isenberg K¹, Sun P^3
1Prescription Solutions, Cost Mesa, CA, USA; ²Purdue University, West Lafayette, IN; ³Eli Lilly and Company, Indianapolis, IN

PDB15
TOTAL CHOLESTEROL, HDL CHOLESTEROL AND HBA_1C AFFECT QUALITY-ADJUSTED LIFE YEARS AND HOSPITAL COSTS FOR PATIENTS WITH TYPE 2 DIABETES IN THE UNITED KINGDOM – THE CARDIFF DIABETES COST UTILITY MODEL
McEwan P¹, Peters JR², Morrissey M³, Bergenheim K⁴, Currie CJ^3
1Cardiff University, Cardiff, Wales, United Kingdom; ²University Hospital of Wales, Cardiff, Wales, United Kingdom; ³Cardiff Research Consortium, Cardiff, Wales, United Kingdom; ⁴AstraZeneca R&D Mölndal, Mölndal, Sweden

PDB16
THE ECONOMIC AND HEALTH OUTCOMES OF USING DIFFERENT INSULIN DELIVERY DEVICES IN A MANAGED CARE ENVIRONMENT
Liu X, Yu W, Yokoyama K
WellPoint Pharmacy Management, West Hills, CA, USA

PDB17
RETIREE TYPE 2 DIABETES HEALTH CARE COSTS FOR A SELF-INSURED TELECOMMUNICATIONS COMPANY
Erwin G¹, Rajagopalan R², Astuto J³, Wilson P⁴, Schaneman J⁵, Kleinman N^5
1Omnicare, Inc, King of Prussia, PA, USA; ²Takeda Pharmaceuticals North America, Lincolnshire, IL, USA; ³Verizon Communications, Alpharetta, GA, USA; ⁴Associates & Wilson, Rosemont, PA, USA; ⁵Options & Choices, Inc, Cheyenne, WY, USA

PDB18
INCREASED HEALTH EXPENDITURES AMONG DIABETES PATIENTS ON INSULIN WITH HYPOGLYCEMIA
Orsini LS¹, Rhoads G², Wang S¹, Zhang Q³, Crown W^1
1The Medstat Group, Inc, Cambridge, MA, USA; ²University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA; ³Aventis Pharmaceuticals, Bridgewater, NJ, USA

PDB19
THE ECONOMIC BURDEN OF TYPE 2 DIABETES MANAGEMENT BY ETHNIC GROUP IN THE TEXAS MEDICAID POPULATION
Lee WC¹, Stephens JM¹, Tran KT¹, Wang Q¹, Dirani RG², Pashos CL^3
1Abt Associates Inc, Bethesda, MD, USA; ²Glaxo Smith Kline, Philadelphia, PA; ³Abt Associates Inc, Cambridge, MA, USA

PDB20
COST-EFFECTIVENESS OF DULOXETINE VERSUS ROUTINE TREATMENT FOR PAINFUL DIABETIC NEUROPATHY IN A RANDOMIZED TRIAL FROM A SOCIETAL PROSPECTIVE
Wu E¹, Birnbaum H¹, Mareva M¹, Le TK², Rosen A², Robinson R², Corey-Lisle P^2
1Analysis Group Inc, Boston, MA, USA; ²Eli Lilly and Company, Indianapolis, IN, USA

DIABETES (including Parathyroid Disease)-Quality Of Life/Patient Preference Studies

PDB21
THE IMPACT OF COMMON DIABETIC COMPLICATIONS ON QUALITY OF LIFE
Holmes JW¹, Hemmett L¹, New JP², Vaughan N³, Sharplin P⁴, Marchant N^5
1Beaufort International, London, United Kingdom; ²Hope Hospital, Salford, United Kingdom; ³Royal Sussex County Hospital, Brighton, United Kingdom; ⁴Aventis Pharma UK, West Malling, Kent, UK; ⁵Pfizer Ltd, Sandwich, Kent, UK

PDB22
THE VALUE TO HIGH-RISK PATIENTS OF PREVENTING A CASE OF DIABETES
Johnson FR, Manjunath R, Hoerger TJ
Research Triangle Institute, Research Triangle Park, NC, USA

PDB23
IS PSYCHOLOGICAL GENERAL WELL-BEING AN IMPORTANT PATIENT-REPORTED OUTCOME FOR THE EVALUATION OF DIABETES DRUG THERAPY?
Hayes RP, Bowman L
Eli Lilly & Company, Indianapolis, IN, USA

PDB24
COMPARE USABILITY OF TWO TYPES OF DISPOSABLE PEN (FLEXPEN VERSUS HUMALOG PEN) CONTAINING RAPID-ACTING INSULIN ANALOGUES
Asakura T¹, Seino H¹, Nicklasson L^2
1Ohta Nishinouchi Hospital, Fukushima, Japan; ²Novo Nordisk Pharmaceuticals Inc, Princeton, NJ, USA

PDB25
PAIN SEVERITY AFFECTS PERCEIVED HEALTH STATUS IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHY
Gore M¹, Brandenburg N², Hoffman D¹, Tai KS^1
1Avalon Health Solutions, Philadelphia, PA, USA; ²Pfizer Global Pharmaceuticals, New York, NY, USA

PDB26
PREFERENCE, EFFICACY, SAFETY AND ACTUAL USE OF BLOOD GLUCOSE (BG) MONITORING WITH INDUO® VS SYRINGE AND SEPARATE METER IN SUBJECTS WITH TYPE 1 DIABETES
Bode B¹, Shelmet J², Gooch B³, Hassman D⁴, Lyness W⁵, Nicklasson L⁵, Schneider S^6
1Atlanta Diabetes Associates, Atlanta, GA, USA; ²123 Franklin Corner Road, Lawrenceville, NJ, USA; ³Melbourne Internal Medicine Associates, Melbourne, FL, USA; ⁴Comprehensive Clinical Research, Berlin, NJ, USA; ⁵Novo Nordisk Pharmaceuticals Inc, Princeton, NJ, USA; ⁶Robert Wood Johnson Medical School, New Brunswick, NJ, USA

DIABETES (including Parathyroid Disease)-Health Policy Studies

PDB27
HOSPITALIZATIONS WITHIN THE VA AMONG VETERANS WITH DIABETES
Wen L¹, Parchman M², Linn W^1
1Audie L. Murphy Division, South Texas Veterans Health Care System, San Antonio, TX, USA; ²University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

DIABETES (including Parathyroid Disease)-Methods
 

PDB28
GLYCEMIC CONTROL AS A CLINICAL OUTCOME VARIABLE: THE IMPACT OF NON-STANDARDIZED MEASURES
Kavookjian J
West Virginia University School of Pharmacy, Morgantown, WV, USA

PDB29
VALIDATION OF THE DIABETES RESOURCE CONSUMPTION INDEX (DRCI): A RISK ADJUSTMENT TOOL FOR PREDICTING HEALTH CARE RESOURCE USE AND COSTS
Joish VN¹, Malone DC², Wendel C³, Mohler MJ^3
1University of Utah, Salt Lake City, UT, USA; ²University of Arizona, Tucson, AZ, USA; ³Southern Arizona VA Health Care System, Tucson, AZ, USA

PDB30
DEVELOPMENT OF A DIABETES RESOURCE CONSUMPTION INDEX (DRCI) USING VETERANS HEALTH ADMINISTRATION DATA
Joish VN¹, Malone DC², Wendel C³, Mohler MJ^3
1University of Utah, Salt Lake City, UT, USA; ²University of Arizona, Tucson, AZ, USA; ³Southern Arizona VA Health Care System, Tucson, AZ, USA

GI DISEASES/DISORDERS 

GI DISEASES/DISORDERS -Clinical Outcomes Studies

PGI1
GASTROINTESTINAL ADVERSE EVENTS FROM NON STEROIDAL ANTI-INFLAMMATORY DRUGS: RELATIONSHIPS BETWEEN RISK ASSESSMENT, VETERANS AFFAIRS PRESCRIBING GUIDELINES, AND HOSPITALIZATION COSTS
Netravali SS¹, Raisch DW¹, Harris CL^2
1Department of Veterans Affairs, Albuquerque, NM, USA; ²VA Cooperative Studies Program, Albuquerque, NM, USA

PGI2
A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF TOTAL AND PARTIAL LAPAROSCOPIC FUNDOPLICATION FOR THE TREATMENT OF GORD.
Boler A¹, Howard P^2
1Heron Evidence Development, Letchworth, Hertfordshire, United Kingdom; ²Heron Evidence Development, Letchworth, Herts, United Kingdom

GI DISEASES/DISORDERS -Cost Studies

PGI3
COST-UTILITY ANALYSIS COMPARING ESOMEPRAZOLE WITH THE ORO-DISPERSIBLE FORMULATION OF LANSOPRAZOLE IN THE INITIAL TREATMENT OF REFLUX OESOPHAGITIS
Plumb J, Edwards S
AstraZeneca UK Ltd, Luton, Bedfordshire, United Kingdom

PGI4
INPATIENT COSTS OF LIVER CIRRHOSIS IN THE UNITED STATES: A RETROSPECTIVE CLAIMS DATA ANALYSIS, 1993-2001
Billah K, Goldstein S, Bower W, Margolis H
Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA

PGI5
COST-EFFECTIVENESS OF TREATING ADULTS WITH CHRONIC HEPATITIS C (CHC) AND PERSISTENTLY NORMAL ALANINE AMINOTRANSFERASE (PNALT) WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS)
Hornberger J¹, Farci P², Prati D³, Zuezem S⁴, Patel KK⁵, Green J^5
1Stanford University & Acumen, LLC, Burlingame, CA, USA; ²Università di Cagliari, Cagliari, TN, Italy; ³IRCCS Ospedale Maggiore, Milan, Italy; ⁴Saarland University Hospital, Homburg/Saar, Germany; ⁵Hoffmann-La Roche Inc, Nutley, NJ, USA

PGI6
ECONOMIC BURDEN OF GERD AND PUD IN AN EMPLOYED POPULATION
Joish VN¹, Donaldson G¹, Stockdale WA¹, Oderda G¹, Brixner DI¹, Sasane R², Joshua-Gotlib S², Crawley JA^2
1University Of Utah, Salt Lake City, UT, USA; ²AstraZeneca LP, Wilmington, DE, USA

PGI7
FECAL LACTOFERRIN ASSAY FOR THE INITIAL DIAGNOSTIC APPROACH TO SYMPTOMATIC PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS: A COST-EFFECTIVENESS ANALYSIS
Ellis JJ, Parsi MA, Lashner BA
Cleveland Clinic Foundation, Cleveland, OH, USA

PGI8
A PHARMACOECONOMIC ASSESSMENT OF THE BENEFITS AND COSTS OF MANAGING IMMUNOSUPPRESSION IN POST-LIVER TRANSPLANT PATIENTS: A UNIVERSITY HOSPITAL PERSPECTIVE
Stolpman NM¹, Valuck RJ², Lezotte D², Malone DC³, Glazner J², Everson GT^2
1University of Colorado Hospital, Denver, CO, USA; ²University of Colorado Health Sciences Center, Denver, CO, USA; ³University of Arizona, Tucson, AZ, USA

GI DISEASES/DISORDERS -Quality of Life 

PGI9
RESPONSIVENESS TO CHANGE AND ENGLISH LANGUAGE VALIDATION OF THE WPAI-GERD QUESTIONNAIRE - RESULTS FROM A CANADIAN STUDY
Wahlqvist P¹, Guyatt G², Armstrong D², Austin P², Barkun A³, Chiba N², degl'Innocenti A¹, El-Dika S⁴, Fallone C³, Heels-Ansdell D², Tanser L⁵, Veldhuyzen van Zanten S⁶, Wiklund I¹, Schünemann H^4
1AstraZeneca R&D Mölndal, Mölndal, Sweden; ²McMaster University, Hamilton, ON, Canada; ³McGill University Health Centre, Montreal, QC, Canada; ⁴University at Buffalo, Buffalo, NY, USA; ⁵AstraZeneca Canada, Mississauga, ON, Canada; ⁶Dalhousie University, Halifax, NS, Canada

PGI10
WORK LOSS AND ACTIVITY IMPAIRMENT DUE TO INFLAMMATORY BOWEL DISEASE
Weston C¹, Sikirica V¹, Pizzi L¹, Goldfarb N¹, Morretti D², Cobb N¹, Howell J¹, Infantolino A², DiMarino A², Cohen S^2
1Jefferson Medical College, Philadelphia, PA, USA; ²Thomas Jefferson University, Philadelphia, PA, USA

GI DISEASES/DISORDERS -Health Policy Studies

PGI11
RETROSPECTIVE ANALYSIS OF A PRIOR AUTHORIZATION PROGRAM USING COX-2 INHIBITORS IN A MANAGED CARE POPULATION
Barlev A¹, Yu W², Johnson K^1
1University of Southern California, Los Angeles, CA, USA; ²WellPoint Pharmacy Management, West Hills, CA, USA  

GI DISEASES/DISORDERS -Methods

PGI12
EVALUATING THE GERD SYMPTOM AND MEDICATION QUESTIONNAIRE (GERD-SMQ) IN A CLINICAL TRIAL
Howell JB¹, Reyes EB², Dylan M², Wade SW², Dodd SL¹, DeLemos BP^1
1Janssen Pharmaceutica, Inc, Titusville, NJ, USA; ²Zynx Health, Beverly Hills, CA, USA
 

INFECTIONS 

INFECTIONS -Clinical Outcomes Studies

PIN1
OUTCOMES OF AN INTERACTIVE VOICE RESPONSE (IVR) REMINDER SYSTEM TO PROMOTE MANAGED CARE ORGANIZATION (MCO) MEMBERS' ATTAINMENT OF INFLUENZA IMMUNIZATION
Sikirica V¹, Crawford A¹, Goldfarb N¹, Nash D¹, Popiel R², Patel M², Wang C², Chu J^2
1Department of Health Policy, Jefferson Medical College, Philadelphia, PA, USA; ²Horizon Blue Cross Blue Shield of New Jersey, Newark, NJ, USA  

PIN2

RETREATMENT RATES OF ACUTE OTITIS MEDIA IN PATIENTS WITH TYMPANOSTOMY TUBES WITHIN THE LOUISIANA MEDICAID PROGRAM
Blake S¹, Waycaster C², Kothari S¹, Myers E¹, Humble L¹, Bollu V^1
1ULM School of Pharmacy, Monroe, LA, USA; ²Alcon Labs Inc, Fort Worth, TX, USA

PIN3

OUTCOMES FOLLOWING THE USE OF AZITHROMYCIN OR CLARITHROMYCIN FOR RESPIRATORY TRACT INFECTIONS IN A MEDICAID POPULATION
Boulanger L¹, Harnett J², Dixon D¹, Menzin J¹, Wilson J^2
1Boston Health Economics, Inc, Waltham, MA, USA; ²Pfizer, Inc, New York, NY, USA

PIN4

EXAMINATION OF HEPATITIS C IN THE LOUISIANA MEDICAID POPULATION
Dalal A, Blake S
University of Louisiana at Monroe, Monroe, LA, USA

PIN5

A META-ANALYSIS OF THREE-DAY AZITHROMYCIN THERAPY VERSUS LONGER COURSES OF COMPARATOR ANTIBIOTICS IN ACUTE SINUSITIS
Harnett J, Enuha S, Xuan J, Cappelleri J
Pfizer, Inc, New York, NY, USA  

PIN6
WITHDRAWN

PIN7

CHANGES IN HIV ANTIVIRAL PHENOTYPIC DRUG RESISTANCE DURING THE HAART ERA
Hess GP, Nelson C, Seiders J
Surveillance Data, Plymouth Meeting, PA, USA

PIN8

AN EVIDENCE BASED PROPOSAL TO MODIFY PRESCRIBING PATTERNS: THE CASE OF METRONIDAZOL USED WHEN INTESTINAL AMOEBIASIS IS SUSPECTED
Medecigo-Micete C, Garduno-Espinosa J, Constantino-Casas P, Gomez-Delgado A, Munoz-Hernandez O
Mexican Institute for Social Security, Mexico City, Mexico

PIN9

VARIABILITY IN THE USE OF HIV PHENOTYPIC TESTING BY SPECIALTY OF PRACTITIONER
Hess GP, Nelson C, Lipskiy N
Surveillance Data, Plymouth Meeting, PA, USA
 

PIN10

OFF-LABEL USE OF PIPERACILLIN/TAZOBACTAM (ZOSYN®) IN A PEDIATRIC UNIT
Thaker DJ¹, Wilson JP², Browne BA¹, Godley PJ^1
1Scott & White Health Plan, Temple, TX, USA; ²University of Texas, Austin, TX, USA  
 

PIN11

TESTING AND TREATMENT OF HEPATITIS C IN THE LOUISIANA MEDICAID POPULATION
Blake SG, Dalal A, Leader WG
The University of Louisiana at Monroe School of Pharmacy, Monroe, LA, USA
 

INFECTIONS -Cost Studies

PIN12
COST-EFFECTIVENESS OF INTRAVENOUS IMMUNOGLOBULIN MANUFACTURED FROM CHROMOTOGRAPHY-CAPRYLATE VS. SOLVENT-DETERGENT METHODS IN PERSONS WITH PRIMARY IMMUNODEFICIENCY DISEASE
Mahadevia PJ¹, Strell J², Kunaprayoon D¹, Gelfand E^3
1MEDTAP International, Bethesda, MD, USA; ²BayerHealth Care, Biological Products Division, LLC, West Haven, CT, USA; ³National Jewish Medical and Research Center, Denver, CO, USA  

PIN13

AN ECONOMIC AND CLINICAL ASSESSMENT OF FIRST-LINE MONOTHERAPY IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA WITHIN MANAGED CARE
Skrepnek GH, Armstrong EP, Malone DC, Ramachandran S
University of Arizona, Tucson, AZ, USA

PIN14

ECONOMIC COST STRUCTURE OF SEVERE SEPSIS MANAGEMENT
Patel AB¹, Jang R², Imhoff T³, Wuestefeld N³, Mueller PJ^3
1Xavier University, New Orleans, LA, USA; ²University of Cincinnati, Cincinnati, OH, USA; ³Good Samaritan Hospital, Cincinnati, OH, USA

PIN15

THE COST OF TREATMENT FAILURE IN ACUTE BACTERIAL MAXILLARY SINUSITIS
Thompson D¹, Amorosi SL¹, Taylor DC¹, Stokes M¹, Asche C², Hadley J³, Ferguson BJ^4
1Innovus Research, Inc, Medford, MA, USA; ²Aventis Pharmaceuticals, Bridgewood, NJ, USA; ³University Otolaryngology Associates, Montgomery, AL, USA; ⁴University ENT Specialists, Inc., Pittsburgh, PA, USA

PIN16

COST-EFFECTIVENESS OF FOUR ANTIMICROBIAL REGIMENS IN PATIENTS ADMITTED TO THE MEDICAL FLOOR WITH CLASS IV OR V COMMUNITY-ACQUIRED PNEUMONIA
Frei CR, Burgess DS
The University of Texas at Austin & The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

PIN17

COST-EFFECTIVENESS MODELING OF TREATMENT APPROACHES TO HEPATITIS C: A MANAGED CARE PERSPECTIVE
Klaskala W¹, Shaya FT², Mullins CD², Law AW¹, Pettit K^1
1Roche Laboratories, Nutley, NJ, USA; ²University of Maryland School of Pharmacy, Baltimore, MD, USA

PIN18

DIRECT TREATMENT COSTS OF TINEA CAPITIS AMONG THE UNITED STATES PRIVATELY INSURED POPULATION
Suh DC¹, Raut M², Chang J², Shin H¹, Gause D², Tavakkol A^2
1Rutgers University, Piscataway, NJ, USA; ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PIN19

THE COST-EFFECTIVENESS ANALYSIS OF COMBINATION OF PEGINTERFERON ALFA-2A AND RIBAVIRIN VERSUS COMBINATION OF PEGINTERFERON ALFA-2B AND RIBAVIRIN IN CHRONIC HEPATITIS C IN POLAND
Orlewska E
Centre for Pharmacoeconomics, Warsaw, Poland

PIN20

BURDEN OF ILLNESS OF BACTERIAL CELLULITIS AND ERYSIPELAS OF THE LEG IN THE NETHERLANDS
Goettsch WG, Panneman MJ, Herings RMC
PHARMO Institute, Utrecht, The Netherlands

PIN21

COMPARISON OF 30-DAY DIRECT MEDICAL COSTS OF AZITHROMYCIN AND LEVOFLOXACIN FOR PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA
Matchar DB¹, Samsa GP¹, Harnett J², Wilson J^2
1Duke University, Durham, NC, USA; ²Pfizer, Inc, New York, NY, USA

PIN22

HOSPITAL UTILIZATION TRENDS OF HIV DISEASE IN THE UNITED STATES, 1993 TO 2001
Zhang HF, Rajiv M, Ciuryla VT
Wyeth Research, Collegeville, PA, USA
 

PIN23

CLINICAL AND ECONOMIC IMPACT OF HERD IMMUNITY ASSOCIATED WITH HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN CANADA
Ford MW¹, Wang ECY¹, Ciuryla V^2
1Wyeth Canada, Markham, ON, Canada; ²Wyeth Research, Philadelphia, PA, USA
 

PIN24

ANTIBIOTIC PRESCRIBING RATES IN AMBULATORY CARE SETTINGS FOR PATIENTS DIAGNOSED WITH INFLUENZA, 1997-2001
Ciesla G¹, Stoddard J², Leader S^1
1MedImmune, Inc, Gaithersburg, MD, USA; ²MedImmune Vaccines, Inc, Gaithersburg, MD, USA

PIN25

COSTS AND OUTCOMES OF EXTENDED-RELEASE CLARITHROMYCIN FOR LOWER RESPIRATORY TRACT INFECTIONS
Halpern MT¹, Cifaldi M², Schmier JK^1
1Exponent, Alexandria, VA, USA; ²Abbott Laboratories, Abbott Park, IL, USA
 

PIN26

MENINGOCOCCAL VACCINE IN PORTUGAL - A COST-EFFECTIVENESS ANALYSIS
Gouveia M¹, Borges M², Tavares L², Portugal R^2
1Universidade Católica Portuguesa, Lisbon, Portugal; ²Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal 

PIN27

THE IMPACT OF PHYSICIAN PROFILING ON ANTIBIOTIC COST AND UTILIZATION.
Ramos K¹, Teng DG¹, Ara SB², Tam JY¹, Keeling F², Finch MJ^1
1Health Net, Oakland, CA, USA; ²Health Net, Woodland Hills, CA, USA

PIN28

MEDICOECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF INFANTILE BRONCHIOLITIS IN FRANCE
Vainchtock A¹, Trichard M², Chaufferin G², Duru G³, Nicoloyannis N⁴, Stagnara J^5
1GYD Institut Groupe IMS Health, Lyon, France; ²BOIRON Laboratories, Sainte-Foy-Lès-Lyon, France; ³Claude Bernard University, Villeurbanne, France; ⁴Lyon 2 University, Bron, France; ⁵Paediatrician, Lyon, France

PIN29

THE ECONOMIC EVALUATION OF INFLUENZA VACCINATION IN THE ELDERLY POPULATION: A MODEL BASED ON BAYESIAN NETWORKS
Baio G¹, Pammolli F¹, Baldo V², Trivello R^2
1University of Florence, Florence, Italy; ²University of Padua, Padua, Italy

PIN30

OBSERVATIONAL STUDY ON THE “REAL LIFE” PRACTICE AND COST OF ANTIBIOTIC (AB) MEDICATION IN PNEUMOCOCCAL PNEUMONIA PATIENTS : PARENTERAL VERSUS STEP DOWN THERAPY (SDT).
Verplanken P¹, Van Wilder P^2
1I